PPLPHARMA · Piramal Pharma Limited · Financials
Volume · Nov 13
288.94K
Avg daily vol (3M)
476.71K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
88.69B
-3.1%
FY2026
Net Income
-3.26B
-457.7%
FY2026
Operating Cash Flow
16.53B
+85.2%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|---|
| INR | 97.79B | 88.69B | 91.51B | 81.71B | 70.82B |
| INR | 8.88B | 8.31B | 8.16B | 7.41B | 6.77B |
| INR | 3.48B | 3.41B | 4.22B | 4.48B | 3.44B |
| INR | 2.33B | 1.5B | 3.24B | 1.61B | 663.1M |
| INR | -2.09B | -3.26B | 911.3M | 178.2M | -1.86B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2026: 1B in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.